PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22421507-1 2013 Numerous experimental studies in recent years have suggested that erythropoietin (EPO) is an endogenous mediator of neuroprotection in various central nervous system disorders, including TBI. Thioacetazone 187-190 erythropoietin Homo sapiens 66-80 22421507-1 2013 Numerous experimental studies in recent years have suggested that erythropoietin (EPO) is an endogenous mediator of neuroprotection in various central nervous system disorders, including TBI. Thioacetazone 187-190 erythropoietin Homo sapiens 82-85 22421507-2 2013 Many characteristics of EPO neuroprotection that have been defined in TBI experimental models suggest that it is an attractive candidate for a new treatment of TBI. Thioacetazone 70-73 erythropoietin Homo sapiens 24-27 22421507-2 2013 Many characteristics of EPO neuroprotection that have been defined in TBI experimental models suggest that it is an attractive candidate for a new treatment of TBI. Thioacetazone 160-163 erythropoietin Homo sapiens 24-27 22421507-3 2013 EPO targets multiple mechanisms known to cause secondary injury after TBI, including anti-excitotoxic, antioxidant, anti-edematous, and anti-inflammatory mechanisms. Thioacetazone 70-73 erythropoietin Homo sapiens 0-3 18789503-7 2009 With the recent interest in clinical trials of EPO in human stroke, it is both timely and prudent to consider the use of this pharmaceutical avenue in TBI in man. Thioacetazone 151-154 erythropoietin Homo sapiens 47-50 17935704-3 2007 This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Thioacetazone 147-150 erythropoietin Homo sapiens 78-81 17935704-12 2007 EPO, administered in its recombinant form, affords significant neuroprotection in experimental TBI model and may hold promise for future clinical applications. Thioacetazone 95-98 erythropoietin Homo sapiens 0-3 30864534-0 2019 Longitudinal Changes in Disability Rating Scale Scores: A Secondary Analysis Among Patients With Severe TBI Enrolled in the Epo Clinical Trial. Thioacetazone 104-107 erythropoietin Homo sapiens 124-127 30864534-7 2019 TBI severity group was found to significantly interact with Epo randomization group on mean DRS recovery curves. Thioacetazone 0-3 erythropoietin Homo sapiens 60-63